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The treatment of high-grade arteriovenous malformations (AVMs) remains challenging. 
Microsurgery provides a rapid and complete occlusion c mpared to other options, but is 
associated with undesirable morbidity and mortality.  
The aim of this study was to compare the occlusion rates, incidence of unfavorable 
outcomes, and cost-effectiveness of embolization and stereotactic radiosurgery (SRS) as 
a curative treatment for high-grade AVMs.  
METHODS 
A retrospective series of 57 consecutive patients wi h high-grade AVM treated with 
embolization or SRS, with the aim of achieving complete occlusion, was analyzed. 
Demographic, clinical, and angio-architectonic variables were collected. Both 
treatments were compared for the occlusion rate and procedure-related complications. 
In addition, a cost-effectiveness analysis was performed.  
RESULTS 
Thirty (52.6%) patients were men and 27 (47.4%) were women (mean age 39 years). 
AVMs were unruptured in 43 (75.4%) patients, and ruptured in 14 (24.6%) patients. 
The presence of deep venous drainage, nidus volume, perforated arterial supply, and 
eloquent localization were more frequent in the SRS group. Complications such as 
hemorrhage or worsening of previous seizures were more frequent in the embolization 








necessary to achieve occlusion between the groups. The incremental cost-effectiveness 
ratio for endovascular treatment vs. SRS was $ 53.279. 
CONCLUSION  
Both techniques achieved similar occlusion rates, but SRS carried a lower risk of 
complications. Staged embolization may be associated with a greater risk of 
hemorrhage, while SRS was demonstrated to have a better cost-effectiveness ratio. 
These results support SRS as a better treatment option for high-grade AVMs. 
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-Radiosurgery seems to be safer than endovascular embolization when used as a 
curative treatment for high-grade AVMs. 
- In high-grade AVMs, a higher number of staged embolization procedures is associated 
with an increased risk of bleeding.  




















Arteriovenous malformations (AVMs) have an incidenc of 1.1/100.000 person-years1 
and are the second major cause of hemorrhagic stroke in young patients. 2,3 An estimate 
indicated that the annual risk of hemorrhage from unruptured AVMs is 2.4%.4 In 
individuals with high-grade AVMs, the annual risk i 1.17 %. 5 
The Spetzler-Martin Scale (SM)6 has been used to classify AVMs according to their 
associated surgical risk, thus identifying a possible management by separating patients 
into two distinct groups: low-grade and high-grade AVMs. Usually, the term low-grade 
refers to grades I and II, and high grade refers to grades IV and V. However, grade III 
did not fit into these two groups. Lawton et al.7 subdivided grade III into four groups: 
S1V1E1 (grade III-), S2V1E0 (grade III), S2V0E1 (grade III+), and S3V0E0 (grade 
III*). S1V1E1 (S: size, V: venous drainage, E: eloquent area) seems to have a low 
surgical risk, similar to grades I and II. Therefor, from a practical perspective, AVMs 
could be classified into 2 categories, leaving S1V1E1 within the low-grade group, and 
including the other grade III lesions in the high-grade group.  
Currently, there are four treatment options for AVM: microsurgery, embolization, 
stereotactic radiosurgery (SRS), and conservative management. Regarding low-grade 








Conversely, there has been a great deal of controversy r garding high-grade AVM 
management9. In particular, debate exists whether one of more treatments can worsen 
the natural history of high-grade AVMs since the partial treatment of these lesions could 
increase the incidence of hemorrhage up to 10.4%10.  
Microsurgery is a challenging option in high-grade AVMs. In these cases, considering 
the high morbidity and mortality11, surgery should be reserved for patients with 
previous hemorrhage, with existing significant permanent deficits, progressive 
neurological deficits related to vascular steal, or an associated arterial or intranidal 
aneurysm10. SRS is an effective management strategy for selected AVMs12. The main 
drawback of this technique is its latency time, or delayed treatment effect, which 
exposes the patient to a higher risk of bleeding during this period.13,14 Another 
important limitation is the risk of radiation-related injury, but advancements in SRS 
techniques such as hypofractionated stereotactic radiotherapy (HST) or stage volume 
SRS (SVR) have been proven to minimize this hazard.15 
Embolization is a common adjuvant to surgery or SRS, providing good results16. 
However, in recent years, due to the significant developments in embolization materials 
and approaches, endovascular procedures have become m re effective with the potential 
for application with a curative intent17,18. However, embolization can be followed by a 
substantial rate of complications, and its safety and efficacy are supported by an 
unsatisfactory retrospective series.19 
Currently, treatment of high-grade AVMs is usually performed using a combination of 
these treatment options. Several studies have compared the results of a single technique 
with the natural history of AVMs or microsurgery, concluding that partial treatment of 
AVMs offered no protection from hemorrhage and is indeed associated with an elevated 








hemodynamic parameters should be taken into account since they could predict AVM 
rupture risk or treatment outcome after each management modality. 4,20–25 
Multidisciplinary and case-to-case consensus decision of an experienced team is the 
normal practice to manage AVMs26,27, especially for high-grade AVMs. Most of these 
cases are treated multimodally, but some cases are treated using a single technique, as 
mentioned earlier, due to the technical advances in the different treatment modalities.15-
17 To the best of our knowledge, SRS and embolization used separately for curative 
treatment of high-grade AVMs have not yet been compared. Therefore, we sought to 
compare the efficacy, safety, and cost-effectiveness of these treatments when applied 




All procedures performed in this study were in accordance with the ethical standards of 
the Institutional Review Board (IRB) and with the 1964 Helsinki Declaration and its 
later amendments or comparable ethical standards. The study protocol was approved by 
the institutional review board (17/026-E_Tesis). Informed consent was waived due to 
the retrospective nature of the study.  
Patient population 
A retrospective series of 144 consecutive patients with high-grade AVMs treated 
between 2000 and 2015 were analyzed. High-grade AVMs were defined as those that 
matched SM grades IV and V and SM grade III fitting the Lawton´s high microsurgical 
risk criteria.7 Patients with high-grade AVM treated with embolization or SRS as single 








latency period was considered sufficient to achieve an effect following SRS. 28,29 
Patients who had not been assessed at least with an annual imaging test, such as a 
conventional arteriography, and MRI 4 years after starting the treatment were also 
excluded. Similarly, patients who underwent microsugery as the main approach for the 
management of AVM were excluded from the study. However, patients who underwent 
surgical procedures to manage hemorrhage-related complications, such as 
ventriculostomy or intracranial hematoma evacuation, a d patients who had a flow-
related aneurysm embolization before radiosurgery were included.  
 
Treatment 
Patients in the endovascular group were treated with staged embolization using onyx as 
an embolic agent. Patients in the SRS group were trated with a single dose (mean dose 
16 Gy, range: 15–16.5 Gy) or HST techniques (5 × 6 Gy, 7 x 3 Gy, and 2 x 10). For 
single-dose treatment, the LINAC Precise system (Elekta, Estocolmo) was used with the 
Philips SRS 200 mechanical system (Shelton/CT, EE).The electron beam energy was 6 
MeV.   
 
Outcomes 
Patient outcomes were assessed by analyzing the main clinical and angio-architectonic 
variables previously suggested as risk factors for complications, hemorrhage, or poor 
outcomes4,6,11,20–25,30. Results and treatment characteristics were assessed u ing data 
obtained from the medical records, pre-treatment arteriography, and 4-year follow-up 
conventional arteriography and MRI. The main variables were occlusion rate, defined as 
the complete occlusion of the AVM observed in a conventional angiogram at the 4-year 








modified Rankin scale (mRS). The mRS was dichotomized into good outcome 
(mRS=0-2) or bad outcome (mRS=3-6).   
 
Statistical Analysis 
For the statistical analyses, the quantitative variables were summarized as mean and 
standard deviation. The qualitative variables were p sented with their frequency 
distribution. A normality test was performed to determine whether to apply parametric 
or non-parametric tests of the quantitative variables to the hypothesis comparison. The 
Shapiro-Wilk test was used in most of the hypothesis test groups, since N < 50. For the 
parametric tests, Student’s t-test and analysis of variance were used to compare the 
means between two groups or 3-or-more categories, respectively. In the non-parametric 
tests, the Mann–Whitney test was used when the categorical variable was distributed in 
two groups and the Kruskal–Wallis test was used when there were three or more 
categories.  
In many of the studies on the independence of variables, the chi-square test was not 
valid because the frequencies at the cross-table box s were < 5. Accordingly, Fisher’s 
exact test was applied. Logistic regression tests were used to identify the risk predictors 
of hemorrhage and unfavorable outcomes. In addition, receiver operating characteristics 
(ROC) curves were obtained. A cost-effectiveness analysis was performed considering 
effectiveness as the complete occlusion rate. Cost values were obtained from the Cost 
and Management Control Service. Overall treatment costs included the costs of the 
planning imaging tests, inpatient hospital stay, treatment procedure, and outpatient 
follow-up.  
In the endovascular group, the costs included each embolization session. Since the 







the mean cost by the number of procedures performed. For the SRS group, the costs 
were obtained from the mean cost of the hypofractionated procedures. Costs from the 
endovascular and SRS groups also included the treatment time, annual imaging tests, 
and outpatient follow-up. Furthermore, for cases that required embolization of a flow-
related aneurysm, the final cost was calculated by adding up each cost.  
Statistical analyses were performed using IBM SPSS statistics version 23 (IBM Corp; 




After applying the inclusion and exclusion criteria, the final sample size was 57 
patients. Thirty (52.6%) were men and 27 (47.4%) were women, with a mean age of 39 
years (range, 4–89 years). Forty-three (75.4%) AVMs were unruptured, while 14 
(24.6%) presented with rupture. Among the bleeding cases, 7 (14%) presented with 
intraventricular hemorrhage. Seven AVMs (12.2%) were discovered incidentally. The 
main presenting features were seizure (49.1%), headache (24.6%), and blood steal 
phenomenon (12.3%), often combined in the same patient at admission. The mean 
AVM diameter was 4.99 cm (range, 3.4–8 cm). In 80.7% of the cases, the AVM 
affected an eloquent area, and in 60% it was associated with deep venous drainage. 
Subject characteristics, clinical features, and AVM angio-architectonic variables are 
summarized in Table 1. 
Embolization was performed in 26 (45.6%) patients, while 31 (54.4%) patients 
underwent SRS. The AVM locations for the two groups are shown in Table 2.  
Most of the patients in the SRS group were treated with HSR, but 4 underwent single-








18.3 (± 3.08) Gy was applied. The embolization group was treated with an average of 
3.91 procedures (± 4.01).  
Overall, both groups were comparable in age, sex, and most of the clinical and angio-
architectonic variables. However, some statistically significant differences were 
observed. In particular, seizures at diagnosis (p=0.05), eloquent location (p=0.009), 
perforated arterial supply (p=0.004), and deep venous drainage (p=0.038) were more 
frequently found in the SRS group than in the embolization group (Table 3). 
Among the patients, 31 (54.4%) presented with complications related to treatment 
(Table 4); hemorrhage in 14 cases (24.5%), worsening or new onset of seizures in 6 
cases (10.5%), and ischemic events in 5 cases (8.8%) were observed. Cyst or radio-
necrosis, edema, and recanalization of the AVMs occurred in 3.5% of cases each. In the 
SRS group, one patient presented with a radiation-induced cyst and another with 
radionecrosis. Symptomatic edema was observed in one SRS-treated case and in one 
case immediately after endovascular embolization. AVM recanalization occurred in 2 
cases after complete endovascular embolization, and was seen at the 2-year follow-up. 
AVMs in the embolization group presented with a stati ically significant number of 
complications (p=0.05) (Table 4). In particular, we found a higher incidence of 
hemorrhage and seizure related to treatment (p=0.007 and p=0.019, respectively), and a 
higher need for salvage surgery for complications (p=0.05) (Table 4). The higher risk of 
hemorrhage in the embolization group was related to bo h AVM nidus diameter and the 
number of drainage veins (p = 0.039 and p = 0.042, respectively), while the number of 
feeders was the variable associated with bleeding in the SRS group (p = 0.002).  
Overall, complete AVM occlusion was achieved in 38 cases (66.7%). No statistically 
significant differences were observed in the occlusion rate between the groups 








between the groups (p=1.00). The time required to achieve AVM occlusion was higher 
in the SRS group than in the embolization group (mean 934.43 days vs. 458.08), 
although this difference did not reach statistical significance (p=0.326). These findings 
are summarized in Table 5.  
A binary logistic regression model was adjusted to evaluate factors that could be 
associated with the occurrence of hemorrhage. The variables included were those 
showing statistically significant differences between both treatment groups, and at the 
same time, associated with the risk of hemorrhage. Accordingly, seizures at 
presentation, type of treatment, presence of vasculr eloquence, nidus volume, eloquent 
location, presence of perforated arterial supply, and deep venous drainage were 
considered. We found that embolization treatment (odds ratio [OR] 0.142, 95% 
confidence interval [CI]: 0.021-0.983; p=0.037) and presence of vascular eloquence 
(OR 5.44, 95% CI: 1.03-28.66; p=0.046) were variables independently associated with 
the occurrence of hemorrhage. Data plotted on the ROC curve showed an acceptable 
discrimination (area under the curve =0.775, p=0.002, 95% CI: 0.828-0.919). Figure 1 
depicts these findings. 
 A binary logistic regression analysis showed that eloquent location and vascular 
eloquence were independent variables for a poor prognosis (OR not determined, CI 95% 
0.000; p=0.002; OR 0.084, CI 95%: 0.010-0.737, p=0.005, respectively). Superficial 
venous drainage was identified as an independent protective factor (OR: 0.061, 95% CI: 
0.006-0.653, p=0.006). However, the ROC curve did not show good discrimination 
(area under the curve =0.474, p=0.769).  
In the cost-effectiveness analysis, effectiveness wa defined as the complete occlusion 








ratio (ICER) was 53.279, suggesting that complete occlusion with embolization of 
AVM would increase the cost by approximately 53.279 USD compared with SRS. 
 
 
DISCUSSION   
AVMs represent relatively rare cerebral lesions that m y be associated with significant 
neurological morbidity and mortality. Their management may require a 
multidisciplinary approach, including surgery, endovascular embolization, and SRS. 
From their natural history, we know that the annual risk of hemorrhage is between 2% 
and 4%, with a variability of 1%–33%, when considering the location and anatomical 
features31,32. During the first year after hemorrhage, the risk of re-bleeding varies from 
6% – 16%. 33 In light of these observations, the decision to treat a ruptured brain AVM 
is less controversial than the decision to treat an unruptured AVM34,35. In recent years, 
AVMs have been treated nonsurgically by embolization and SRS with growing results. 
When possible, surgical resection is often preferred b cause it can provide removal of 
the lesion and eliminate the risk of future bleeding. However, surgical resection of 
AVMs presents perioperative morbidity and mortality, the incidence of which increase 
with the number of SM grades36,37. In this scenario, a small AVM, deeply located and/or 
in eloquent locations, can be safely treated by SRS. Targeted endovascular embolization 
can be a solution for an AVM that has bled, because it may decrease the risk of 
subsequent hemorrhage and reduce radioresistant spots during the latency period 
following SRS or allow a subsequent complete microsu gical excision10.  
To date, there is no consensus regarding the management of high-grade AVMs10,38,39,40 
Several studies suggest that the relative risk of hemorrhage in high-grade AVMs 








Curative treatment of high-grade AVMs is rarely a realistic goal41. Ideally, the 
definitive treatment would be a complete eradication of the vascular malformation; 
however, the risks of operative morbidity and mortality are known to range between 
17% and 38.4%6,7,10, 42,43. To compound the situation, the results of the ARUBA trial (a 
randomized trial of unruptured brain AVMs) have suggested that medical management 
is superior to interventional therapy for unruptured AVMs3. Although the conclusion of 
this trial has become almost controversial44, we have to deal with this evidence, which 
has had a concrete effect on physicians' decision-making regarding the treatment of 
unruptured AVMs. Accordingly, the dilemma for treating high-grade AVM still 
exists, and data pertaining to the outcomes of conservative management versus 
intervention for these vascular lesions are both limited and conflicting. The TOBAS 
trial aims to compare the conservative versus interventional treatment for unruptured 
AVMs in terms of stroke and death from any cause at 10 years45.  
In this retrospective study, we evaluated the results of a series of high-grade AVMs 
treated by SRS or embolization, each used with a cur tive intention, and compared the 
efficacy, safety, and cost-effectiveness of both treatments. Overall, we found that 
perforated arterial supply, deep venous drainage, and eloquent locations, were more 
frequent in the SRS group, thus increasing the complexity of AVMs in this group 
compared with those in the embolization group. Although these findings could lead to a 
worse outcome in the SRS group, embolized patients pre ented with a higher incidence 
of hemorrhage and seizure related to treatment, and a higher need for salvage surgery 
for complications than the patients treated with SRS.   
Based on established evidence that the time for AVM closure following SRS varies 
between 21 and 48 months28, our cases were monitored for at least 4 years. Of note, 








years. However, extending the observation time if the AVM is still open, may expose 
SRS-treated AVM to a worse course compared to its natural history10.   
In our series, the most frequent clinical presentation was seizures, although some 
authors have observed that the most common clinical presentation was hemorrhage4, 
30,46. However, this discrepancy is due to the fact that most of the reported series 
investigated low-grade AVMs in which the most frequnt diagnosis was bleeding 47,48, 
while high-grade AVMs tend to clinically manifest as seizures.49 
 
Complications rate and bad outcomes 
Some scales have been described to predict the risks of complications or bad outcomes 
of curative treatment with embolization of AVMs, such as the Buffalo, Puerto Rico, and 
AVM embocure scores 22–24. In our series, the average number of feeders was 3.32 
(±1.9). This value corresponds to a medium risk based on the Puerto Rico and Buffalo 
scores, and a low risk based on the AVM embocure score. The mean diameter of the 
feeders was 1.79 (±0.52), corresponding to a low-risk Buffalo score. However, the 
percentage of complications was 65.4% in the embolization group. The mean number of 
procedures performed to achieve complete obliteration was 3.91(SD=4.011). Starke et 
al.50 observed that staged embolization using more than one procedure is an independent 
risk factor for complications. Hartmann et al.51 observed that severe complications 
occurred when the number of procedures was ≥ 3.4. The number of procedures 
performed in our series was higher than recommended; thus, the higher rate of 
complications observed in our experience can be related to the number of occlusion 
attempts. Accordingly, it should be taken into account that hemorrhage is a well-known 
and predictable complication of multiple embolization procedures when trying to 








Most of the AVMs in the SRS group were treated with HSR with different planning 
schemes, considering that the effect of such a treatment is dose-dependent52. The 
clinical target volume was completely covered in 54.8% of cases. In cases where full 
coverage was not possible, when planning the target volume, we attempted to cover the 
feeder region of the nidus. Considering that SRS has a concentric proliferative effect on 
the vessels53, we hypothesized that by targeting the AVM feeders, the flux inside the 
vascular lesion would stop. A single dose technique was performed in 4 out of 31 
patients, obtaining complete AVM obliteration in one case.  
Deep venous drainage has been described as a risk factor for poor outcomes or 
hemorrhage32. Frequently, deep ventricular, paraventricular, and brainstem locations 
have been associated with exclusive deep venous drains and deep localization, 
described as a risk factor for hemorrhage54. In our series, these associations were not 
found. However, we observed that the superficial venous system can be a protective 
factor for hemorrhage, although investigation of this aspect has been scarcely reported 
in the literature. 
Nevertheless, in the present series, we found that the complication rate of SRS or 
embolization of high-grade AVMs as a single treatment with curative intent, was higher 
than the results published for microsurgery series6,11. Han et al.10 recommended 
complete occlusion of the high-grade AVMs using a combination of treatments in cases 
with previous severe hemorrhage. In the present series of 144 treated high-grade AVMs, 
only 57 patients were selected for the analysis of the safety and occlusion rate of SRS or 
embolization as a single treatment. Considering these r sults, the best management is 
conservative management, and combined treatment only for some selected cases.  
 








In our series, the overall occlusion rate was 66.7 %  In particular, the occlusion rate was 
77% in the embolization group, and 58.1% in the SRS group. However, these 
differences were not statistically significant. The occlusion rate achieved in our series 
was higher than that reported in the literature, although the overall clinical complication 
rate was also greater19 (Table 3). The opposite findings were observed in the SRS 
group, where a lower obliteration rate and a substantially lower complication rate were 
observed.  
Our findings, however, are in line with those previously published. In particular, for 
giant AVM, Chung et al. reported an obliteration rate of 22.8% and 47.5% for dose-
staged and volume-staged groups, respectively, withclinical improvement in the 
symptoms 55. In addition, Xiao et al. obtained a significant volume reduction in giant 
AVMs without increasing the risk of hemorrhage56. 
In our study, the average time to achieve AVM occlusion was longer in the SRS group 
than in the embolization group, although no statistically significant differences were 
found between both groups. Conceptually, when considering low-grade AVMs, 
embolization seems to be an immediately effective treatment, similar to microsurgery. 
However, this is not the case with high-grade AVMs, since embolization used in a 
staged fashion requires a long period until the treatm nt is completed. During the time 
elapsed, high-grade AVMs might be exposed to a highrisk of bleeding, similar to that 
observed for SRS10.  
 
Cost-effectiveness analysis 
Compared to embolization, SRS resulted in a lower economic burden for the treatment 
of high-grade AVMs. According to our review of the literature, no studies have 







related to non-complicated procedures were included. In the embolization group, the 
complication rate was 65.4%, and 45% in the SRS group. Therefore, if the additional 
costs for treating complications had been included (i. ., costs for increased hospital stay, 
imaging testing, and other procedures), the ICER would have increased substantially. 
Likewise, the costs derived from salvage surgery, which was more common in the 
embolization group, were not included. If they had been considered, they would also 
have raised the ICER.  
 
When comparing our results with those reported in surgical series6,11,57, neither SRS nor 
embolization seems to have additional benefit. Conservative treatment or 
multidisciplinary management should be chosen for selected patients. Nevertheless, 
SRS seems to be safer than embolization as a single treatment and achieves a similar 




The main limitation of this study is its retrospective nature, which could include 
selection bias. Prospective trials, as the TOBAS study, will provide more consistent 
information58. However, the characteristics of the AVMs for both groups were 
comparable when considering the analyzed variables. Another limitation is the sample 
size. However, the incidence of AVMs is estimated to be 1.1/100,000 person-years1, 
and much lower than that of high-grade AVM. For insta ce, in the ARUBA study3, 62 
out of 226 AVMs were SM grade III, 23 were grade IV, and none were grade V. Taken 
collectively, our 57 high-grade AVMs represent a series-of-note where, for the first 








intent were analyzed. Finally, the number of ruptured AVMs was lower than that of 
bleeding lesions. However, the small number of ruptured AVMs (14 cases out of 57) 
does not add significant bias to the statistical evaluation. In contrast, analysis of 
unruptured AVMs may provide further insight into these vascular lesions that are more 
likely to lead to a poor outcome if left untreated10.  
 
CONCLUSIONS  
SRS and embolization of high-grade AVMs as a single treatment with the aim of 
complete occlusion showed a high incidence of complication, although SRS carries a 
lower risk of complications, and staged embolization may be associated with a greater 
risk of hemorrhage. However, both techniques can provide similar occlusion rates, with 
SRS offering better cost-effectiveness. We believe that our results can provide data for 
further robust systematic reviews and meta-analyses u ful in tailoring more reliable 
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ROC curve expressing the model obtained to predict a hemorrhagic event while 
considering endovascular treatment and vascular eloqu nce as variables. (AUC=0.775, 
p=0.002 (95%, CI 0.828-0.919). Overall, embolization treatment and presence of 
vascular eloquence were variables independently associated with hemorrhagic 
occurrence.  A binary logistic regression analysis showed that eloquent location and 
vascular eloquence were independent variables for a poor prognosis (OR not 
determined, CI 95% 0.000; p=0.002; OR 0.084, CI 95%: 0.010-0.737, p=0.005, 
respectively). Superficial venous drainage was ident fi d as an independent protective 
factor (OR: 0.061, 95% CI: 0.006-0.653, p=0.006). However, the ROC curve did not 





Figure showing the summary of the Cost-effectiveness analysis performed.  
Treatment costs included the costs of the planning imaging tests, hospital inpatient stay, 







included each embolization session. For the SRS group, the costs were obtained from 
the mean cost of the hypofractionated procedures. For those cases needing embolization 
of a flow-related aneurysm, the final cost merged by adding up each cost.  
The ICER was 53.279 thus suggesting that AVM complete occlusion by embolization 
would increase the cost approximately of 53.279 USD when compared with SRS. 
SRS, Stereotactic Radiosurgery; CEA, cost-effectiveness Analysis; ΔC, incremental 









TABLE 1.  Subject Characteristics and Descriptive of AVMs Variables  
 








57 26 31  
Demographic      
Age in yr. (mean, range & ±SD) 39 (4-89) 41.4 (± 15.8) 38.45 (±16.0) 0.64 
Male    (n, %) 30 (52.6) 11 ( 37.9) 18 (62.1) 0.18 
Female (n, %) 27 (47.4) 15 (55.6) 12 (44.4) 
     
Clinical Variables at presentation      
GCS at presentation (mean ± SD) 13±1.6 13.85 ± 1.1 13.77 ± 1.5 0.44 
Incidental     (%) 7 11.5 6.4 0.33 
Hemorrhage (%) 87.8 32.2 30.8 0.84 
          I.V. Hemorrhage (%) 14 48.9 51.1 0.71 
                 I.V. Hemorrhage volume <30cc 
(%) 
93 96.1 83.9 0.61 
                 I.V. Hemorrhage volume >30cc 
(%) 
7 3.9 16.1 
Headache (%) 24.6 26.9 22.6 0.76 
Blood steal phenomenon (%) 12.3 7.7 16.12 0.43 
Seizures at diagnosis (n., %)  34 58.1 0.05* 
     
AVM location     
Deep AVM location * (%) 10.7 6.45 12.9 0.17 
Eloquence of location (%) 80.7 65.4 90.3 0.009* 
Supratentorial lobar† (%) 98.2 100 96.8 1.00 
Ventricular/ Paraventricular (%) 1,7 0 3.2 1.00 
Brainstem (%) 0 0 0 . 
Cerebellum (%) 1.8 0 3.2 1.00 
     
Angioarchitectonic & location 
Variables                    
    








Number of feeders (mean ± SD) 3.32 ± 1.9 3.69 (±1.9) 2.65 (±1.8) 0.085 
Vascular eloquence (%) 42.1 38.5 45.2 0.53 
Diameter of feeders in mm (mean ± SD ) 1.79 ± 0.52 1.89 ± 0.53 1.7 ± 0.51  
Perforating artery supply (%) 61.4 42.3 77.4 0.004* 
Nidus largest diameter in cm (mean range) 
or (mean ± SD) 
4.99 (3.4-8) 4.89 ±1.12 5.13±1.35 0.56 
Nidus volume in cm3 (mean ± SD) 12.66 ± 11.82 5.36 ± 4.87 18.8 ± 12.5 0.000* 
Diffuse (%) 35.1 26.9 35.5 0.44 
Aneurysm (%) 19.6 30.7 9.7 0.052 
Fistulous components (%) 35.1 73 58 0.30 
Number of drainage vein (mean ± SD) 2.46 ± 2 2.23(±0.95) 2.65 (±1.1) 0.154 
Presence of venous aneurysm or stenosis 
(%) 
24.5 23 25.8 1.00 
For clinical variables at presentation 22.8% of cases presented with two or more symptoms. 
*  Deep location refers to the basal ganglia, thalamus, or brainstem; † Supratentorial lobar location,  
frontal, temporal, parietal, or occipital; GCS , Glasgow Coma Scale; I.V., Intraventricular;  
















Seizures at diagnosis (n., %)  9 (34) 18 (58.1) 0.05* 
Nidus diameter (cm, SD)  4.9 (±1.12) 5.13(± 1.25) 0.56 
Number of veins (mean, SD) 2.23(±0.95) 2.65 (±1.1) 0.154 
Number of feeders (mean, SD) 3.69 (±1.9) 2.65 (±1.8) 0.085 
Eloquent location (n., %)  17 (65.3) 28 (90.3) 0.009* 
Perforating artery supply (n., %)  11 (42.3) 24 (77.4) 0.004* 
Deep venous drainage (n., %)  12(46.1) 22 (71) 0.038* 
 
 



















Overall complication Rate (n., %) 31 (54.4) 17 (65.4) 14 (45) 0.050 
Hemorrhage (n., %) 14 (24.5) 11 (42.3) 3 (10) 0.007 
Seizures (n., %) 6 (10.5) 5 (19.2) 1 (3.2) 0.019 
Ischemia (n., %) 5 (8.8) 3 (11.5) 2 (6.5) 0.155 
Cyst or radio-necrosis (n., %) 2 (3.5) 0 2 (3.5) 0.301 
Edema (n., %) 2 (3.5) 1 (3.8) 1 (3.2) 0.157 
AVM recanalization (n., %) 2 (3.5) 2 (3.5) 0 0.212 
Surgery for complications (n., %) 14 (24.6) 10 (38.4) 4 (13) 0.050 
 


















Occlusion Rate (n., %) 
 
38 (66.7) 20 (77) 18 (58.1) 0.184 
mRS at follow-up 
 
    
       Favorable (0-2) (%) 
 
89.3 48 52  
1.000 
       Unfavorable (3-6) (%) 
 
10.7 50 50  
Time to occlusion (days, SD) 675,54 (±1239,3) 458,08 (± 675,6)  934,43 (± 1666,9) 0.326 
 










TABLE 2. AVM Location between the treatment groups 
 
 
 Embolization (n. 
26) 
SRS (n. 31) P value  
    
Laterality Left 11(42,3%)  17 (54.8%) 0.341 
Right 15 (57.7%) 14 (45.2%) 
    
Eloquent location 18 (69.2%) 28 (90.3%) 0.009 




1  21 (80.7%) 25 (80.6%) 1.000 
≥ 2 5 (19.2%) 5 (16.1%) 
    
Frontal  9 (34.6%) 9 (29%) 0.505 
Temporal  10 (38.4%) 8 (25.8%) 0.346 
Parieto-occipital  7 (27%) 12 (38.7%) 0.333 
Ventricular/ 
Paraventricular 
0 1 (3.2%) 1.000 
Cerebellum 0 1 (3.2%) 1.000 
    
Deep Location*  10 (38.4%) 11 (35.5%) 0.172 
    
 























Abbreviations :  
 
 
AVM: arteriovenous malformations 
AVMES: Embocure score 
CEA: cost-effectiveness analysis 
E: eloquent area 
HST: hypofractionated stereotactic radiotherapy 
ICER: Incremental cost-effectiveness ratio 
MRI: Magnetic resonance imagine  
mRS: modified Rankin scale 
S: size 
SM: Spetzler-Martin Scale 
SRS: Stereotactic radiosurgery  
SVR: stage volume radiosurgery  
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